AlphaStocks

AZN vs CPRX

ASTRAZENECA PLC vs CATALYST PHARMACEUTICALS, INC. — Side-by-Side Stock Comparison

AZN

ASTRAZENECA PLC

8.4

Strong Buy

$200.99

CPRX

CATALYST PHARMACEUTICALS, INC.

6.4

Consider Buy

$24.83

AZN vs CPRX: Which is the Better Investment?

ASTRAZENECA PLC (AZN) scores 8.4/10 while CATALYST PHARMACEUTICALS, INC. (CPRX) scores 6.4/10 on AlphaStocks' composite model. ASTRAZENECA PLC has the higher composite rating of Strong Buy. On a P/E basis, CATALYST PHARMACEUTICALS, INC. trades at 14.7x, making it the more attractively priced of the two.

This comparison is algorithmically generated and is not financial advice.

MetricAZNCPRX
Scores & Fundamentals
Composite Score8.4/106.4/10
RatingStrong BuyConsider Buy
Price$200.99$24.83
P/E Ratio30.414.7
ROE21.9%22.9%
Market Cap$312B$3B
Fair Value$192.63
Dividend Yield1.6%
Sector Rank#3 of 1127#197 of 1127
Model Verdicts
PiotroskiStrongNeutral
BuffettStrongAttractive
GrahamCautionNeutral
LynchNeutralStrong
GreenblattNeutralLimited Data
View full AZNanalysis →View full CPRXanalysis →
Compare any two stocks →

AZN vs CPRX: Which Stock Scores Higher?

ASTRAZENECA PLC (AZN) and CATALYST PHARMACEUTICALS, INC. (CPRX) are among the most compared stocks in the Health Care sector. AZN currently leads with a composite score of 8.4/10 (Strong Buy) compared to CPRX's 6.4/10 (Consider Buy).

The AlphaStocks composite score evaluates each stock across four dimensions: Quality (business strength measured by Piotroski F-Score and Buffett quality criteria), Value (discount to intrinsic worth using Graham, Lynch, and Greenblatt models), Momentum (6-month price trend), and Timing (a confirmation signal that requires both value and momentum to align). A higher composite score indicates stronger overall fundamentals combined with favorable market conditions.

This comparison uses the same scoring framework for both companies, ensuring an apples-to-apples evaluation. Scores are recalculated daily after market close using data from SEC filings and market prices. Read the full methodology to understand how each model contributes to the composite score.

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer